Novel reversible selective inhibitor of nuclear export shows that CRM1 is a target in colorectal cancer cells

Cancer Biology and Therapy

Volumn 16, Issue 7, 2015, Pages 1110-1118

  Niu, Mingshan ^a   Chong, Yulong ^a   Han, Yan ^b   Liu, Xuejiao ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

^b Dalian Centers for Disease Prevention and Control   (China)

Author keywords

Colorectal cancer; CRM1; Nuclear export; Proliferation; S109

Indexed keywords

ANTINEOPLASTIC AGENT; EXPORTIN 1; PROTEIN INHIBITOR; S 109; UNCLASSIFIED DRUG; AMINOPYRIDINE DERIVATIVE; CELL CYCLE PROTEIN; CELL RECEPTOR; CYCLOPENTANE DERIVATIVE; EXPORTIN 1 PROTEIN; KARYOPHERIN; NUCLEAR PROTEIN; RAN-BINDING PROTEIN 1; S109 COMPOUND;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CELL ADHESION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL INVASION; CELL PROLIFERATION; CELL VIABILITY; CELLULAR DISTRIBUTION; CLONOGENIC ASSAY; COLONY FORMATION; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; CYTOPLASM; G1 PHASE CELL CYCLE CHECKPOINT; HT 29 CELL LINE; HUMAN; HUMAN CELL; NUCLEAR EXPORT SIGNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; ACTIVE TRANSPORT; ANTAGONISTS AND INHIBITORS; CELL NUCLEUS; CHEMICAL STRUCTURE; CHEMISTRY; COLORECTAL TUMOR; DOSE RESPONSE; DRUG EFFECTS; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENETICS; HT-29 CELL LINE; METABOLISM; MUTATION; PATHOLOGY; TUMOR CELL LINE; TUMOR STEM CELL ASSAY; WESTERN BLOTTING;

ACTIVE TRANSPORT, CELL NUCLEUS; AMINOPYRIDINES; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CYCLOPENTANES; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINTS; HT29 CELLS; HUMANS; KARYOPHERINS; MICROSCOPY, FLUORESCENCE; MOLECULAR STRUCTURE; MUTATION; NUCLEAR PROTEINS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TUMOR STEM CELL ASSAY;

EID: 84943769590     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2015.1047569     Document Type: Article

References (32)

1. Fang Y, Yu H, Liang X, Xu J, Cai X. Chk1-induced CCNB1 overexpression promotes cell proliferation and tumor growth in human colorectal cancer. Cancer Biol Ther 2014; 15: 1268-79; PMID: 24971465; http://dx. doi. org/10. 4161/cbt. 29691.
2. Tong JH, Lung RW, Sin FM, Law PP, Kang W, Chan AW, Ma BB, Mak TW, Ng SS, To KF. Characterization of rare transforming KRAS mutations in sporadic colorectal cancer. Cancer Biol Ther 2014; 15: 768-76; PMID: 24642870; http://dx. doi. org/10. 4161/cbt. 28550.
3. Sugarbaker PH, Ryan DP. Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach? Lancet Oncol 2012; 13: e362-9; PMID: 22846841; http://dx. doi. org/10. 1016/S1470-2045(12)70210-3.
4. Gallant JN, Allen JE, Smith CD, Dicker DT, Wang W, Dolloff NG, Navaraj A, El-Deiry WS. Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. Cancer Biol Ther 2011; 12: 239-51; PMID: 21725213; http://dx. doi. org/10. 4161/cbt. 12. 3. 17034.
5. Bogaert J, Prenen H. Molecular genetics of colorectal cancer. Ann Gastroenterol 2014; 27: 9-14; PMID: 24714764.
6. Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S, Lozano G, Pikarsky E, Forshew T, Rosenfeld N, et al. Mutant p53 prolongs NF-kappaB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 2013; 23: 634-46; PMID: 23680148; http://dx. doi. org/10. 1016/j. ccr. 2013. 03. 022.
7. Berg M, Soreide K. EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy. Discov Med 2012; 14: 207-14; PMID: 23021375.
8. Bottini C, Platini F, Rinaldi M, Leutner M, Alabiso O, Garavoglia M, Tessitore L. p27Kip1 is inactivated in human colorectal cancer by cytoplasmic localization associated with activation of Akt/PKB. Int J Oncol 2009; 34: 69-77; PMID: 19082479.
9. Cheah PY, Choo PH, Yao J, Eu KW, Seow-Choen F. A survival-stratification model of human colorectal carcinomas with beta-catenin and p27kip1. Cancer 2002; 95: 2479-86; PMID: 12467060; http://dx. doi. org/10. 1002/cncr. 10986.
10. Nguyen KT, Holloway MP, Altura RA. The CRM1 nuclear export protein in normal development and disease. Int J Biochem Mol Biol 2012; 3: 137-51; PMID: 22773955.
11. Mor A, White MA, Fontoura BM. Nuclear trafficking in health and disease. Curr Opin Cell Biol 2014; 28: 28-35; PMID: 24530809; http://dx. doi. org/10. 1016/j. ceb. 2014. 01. 007.
12. Wang Y, Xiang J, Ji F, Deng Y, Tang C, Yang S, Xi Q, Liu R, Di W. Knockdown of CRM1 inhibits the nuclear export of p27(Kip1) phosphorylated at serine 10 and plays a role in the pathogenesis of epithelial ovarian cancer. Cancer Lett 2014; 343: 6-13; PMID: 24018641; http://dx. doi. org/10. 1016/j. canlet. 2013. 09. 002.
13. Shen A, Wang Y, Zhao Y, Zou L, Sun L, Cheng C. Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery 2009; 65: 153-9; discussion 9-60; PMID: 19574837; http://dx. doi. org/10. 1227/01. NEU. 0000348550. 47441. 4B.
14. Zhang K, Wang M, Tamayo AT, Shacham S, Kauffman M, Lee J, Zhang L, Ou Z, Li C, Sun L, et al. Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Exp Hematol 2013; 41: 67-78 e4; PMID: 22986101; http://dx. doi. org/10. 1016/j. exphem. 2012. 09. 002.
15. Tan DS, Bedard PL, Kuruvilla J, Siu LL, Razak AR. Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy. Cancer Discov 2014; 4: 527-37; PMID: 24743138; http://dx. doi. org/10. 1158/2159-8290. CD-13-1005.
16. Parikh K, Cang S, Sekhri A, Liu D. Selective inhibitors of nuclear export (SINE)-a novel class of anti-cancer agents. J Hematol Oncol 2014; 7: 78; PMID: 25316614; http://dx. doi. org/10. 1186/s13045-014-0078-0.
17. Liu X, Niu M, Xu X, Cai W, Zeng L, Zhou X, Yu R, Xu K. CRM1 is a direct cellular target of the natural anti-cancer agent plumbagin. J Pharmacol Sci 2014; 124: 486-93; PMID: 24739265; http://dx. doi. org/10. 1254/jphs. 13240FP.
18. Turner JG, Dawson J, Sullivan DM. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol 2012; 83: 1021-32; PMID: 22209898; http://dx. doi. org/10. 1016/j. bcp. 2011. 12. 016.
19. Newlands ES, Rustin GJ, Brampton MH. Phase I trial of elactocin. Br J Cancer 1996; 74: 648-9; PMID: 8761384; http://dx. doi. org/10. 1038/bjc. 1996. 415.
20. Senapedis WT, Baloglu E, Landesman Y. Clinical translation of nuclear export inhibitors in cancer. Semin Cancer Biol 2014; 27: 74-86; PMID: 24755012; http://dx. doi. org/10. 1016/j. semcancer. 2014. 04. 005.
21. Turner JG, Dawson J, Cubitt CL, Baz R, Sullivan DM. Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents. Semin Cancer Biol 2014; 27: 62-73; PMID: 24631834; http://dx. doi. org/10. 1016/j. semcancer. 2014. 03. 001.
22. Mau-Soerensen M, Razak ARA, Mahipal A, Mahaseth H, Gerecitano JF, Shacham S, Yau CYF, Lassen U, Shields AF, McCauley D, et al. Safety and antitumor activity of selinexor (KPT-330), a first-in-class, oral XPO1 selective inhibitor of nuclear export: A phase I study expanded with colon cancer cohort. J Clin Oncol 2014; 32: 482; abstract; PMID: 24395844; http://dx. doi. org/10. 1200/JCO. 2013. 53. 3448.
23. Sakakibara K, Saito N, Sato T, Suzuki A, Hasegawa Y, Friedman JM, Kufe DW, Vonhoff DD, Iwami T, Kawabe T. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood 2011; 118: 3922-31; PMID: 21841164; http://dx. doi. org/10. 1182/blood-2011-01-333138.
24. Hilliard M, Frohnert C, Spillner C, Marcone S, Nath A, Lampe T, Fitzgerald DJ, Kehlenbach RH. The antiinflammatory prostaglandin 15-deoxy-delta(12, 14)-PGJ2 inhibits CRM1-dependent nuclear protein export. J Biol Chem 2010; 285: 22202-10; PMID: 20457605; http://dx. doi. org/10. 1074/jbc. M110. 131821.
25. Sun Q, Carrasco YP, Hu Y, Guo X, Mirzaei H, Macmillan J, Chook YM. Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1. Proc Natl Acad Sci U S A 2013; 110: 1303-8; PMID: 23297231; http://dx. doi. org/10. 1073/pnas. 1217203110.
26. Ewing I, Hurley JJ, Josephides E, Millar A. The molecular genetics of colorectal cancer. Frontline Gastroenterol 2014; 5: 26-30; PMID: 24416503; http://dx. doi. org/10. 1136/flgastro-2013-100329.
27. Kau TR, Schroeder F, Ramaswamy S, Wojciechowski CL, Zhao JJ, Roberts TM, Clardy J, Sellers WR, Silver PA. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell 2003; 4: 463-76; PMID: 14706338; http://dx. doi. org/10. 1016/S1535-6108(03)00303-9.
28. Jirawatnotai S, Sharma S, Michowski W, Suktitipat B, Geng Y, Quackenbush J, Elias JE, Gygi SP, Wang YE, Sicinski P. The cyclin D1-CDK4 oncogenic interactome enables identification of potential novel oncogenes and clinical prognosis. Cell Cycle 2014; 13: 2889-900; PMID: 25486477; http://dx. doi. org/10. 4161/15384101. 2014. 946850.
29. Mendonca J, Sharma A, Kim HS, Hammers H, Meeker A, De Marzo A, Carducci M, Kauffman M, Shacham S, Kachhap S. Selective inhibitors of nuclear export (SINE) as novel therapeutics for prostate cancer. Oncotarget 2014; 5: 6102-12; PMID: 25026284.
30. Daelemans D, Afonina E, Nilsson J, Werner G, Kjems J, De Clercq E, Pavlakis GN, Vandamme AM. A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. Proc Natl Acad Sci U S A 2002; 99: 14440-5; PMID: 12374846; http://dx. doi. org/10. 1073/pnas. 212285299.
31. Niu M, Sun Y, Liu X, Tang L, Qiu R. Tautomycetin induces apoptosis by inactivating Akt through a PP1-independent signaling pathway in human breast cancer cells. J Pharmacol Sci 2013; 121: 17-24; PMID: 23269238; http://dx. doi. org/10. 1254/jphs. 12206FP.
32. Liu X, Cai W, Niu M, Chong Y, Liu H, Hu W, Wang D, Gao S, Shi Q, Hu J, et al. Plumbagin induces growth inhibition of human glioma cells by downregulating the expression and activity of FOXM1. J Neurooncol 2015; 121: 469-77; PMID: 25528634; http://dx. doi. org/10. 1007/s11060-014-1664-2.